Novartis: Gilenya Speaker Payments and the Talks That Never Happened

Novartis’ Gilenya case centers on allegations that the company used speaker fees and meals to buy prescriptions for its multiple sclerosis drug. A former sales specialist alleged that Novartis paid doctors for canceled talks, held events for audiences already familiar with the drug, and offered speaking work to influence prescription volume. If you worked on the invitations, payments or sales targets, those decisions may be familiar.

In March 2026, the federal court in New York let the case go forward.

Gilenya Speaker Programs and the Prescribers They Paid

Gilenya posed a practical challenge for medical offices. As the appeals court explained, the drug can slow a patient’s heart rate, and the Food and Drug Administration required doctors to monitor new patients on an electrocardiogram machine for at least six hours after the first dose. That burden made winning over prescribers especially important.

The alleged speaker program kickbacks ran through two formats. Patient Events addressed prospective patients. Peer-to-Peer events addressed other healthcare professionals. According to the court’s account of the allegations, speakers received $1,500 to $3,500 per event, usually at high-end restaurants.

The whistleblower behind the qui tam case had worked in Gilenya sales in the Philadelphia area. His complaint alleged that the payments induced prescribing and caused false claims to Medicare, Medicaid, TRICARE and Veterans Administration Health Care. In that alleged scheme, taxpayers funded prescriptions bought with speaker fees.

The complaint also described staff questioning the value of repeated patient events. The alleged response from management put the speaker at the center:

One Purpose of the Payment Was Enough

In its December 27, 2024 opinion, the Second Circuit said that buying prescriptions for a drug covered by federal health care programs need only be one purpose of a payment for it to violate the Anti-Kickback Statute. The payment could have other purposes too.

An educational presentation can sit alongside an effort to buy prescriptions. The court examined the audience, the compensation and the selection of speakers together, and revived three categories of allegations.

Three Speaker-Program Allegations the Court Revived

The appeal restored allegations about audiences with little reason to attend, payments for canceled events and speaking work used to reward or influence prescribing. The court’s examples show the business decisions behind each category.

1. Speakers Presenting to Other Speakers

One alleged event put a paid speaker in front of two other Novartis speakers over a steak dinner in Florida. The alleged dinner bill was $1,080. Other examples described speakers presenting only to colleagues and staff from their own practices.

The court considered the audience’s existing familiarity with Gilenya alongside the upscale setting. A dinner among people who already knew the drug could support the allegation that paying and entertaining prescribers was one purpose of the event.

The earlier complaint supplied another view from inside the program. It alleged that patient events repeatedly attracted the same audience, sometimes to the same presentation twice in a week. For someone who handled invitations or attendance, the guest list tells more than the headcount. It can connect the people at the table with the people already paid to promote the drug.

2. Canceled Events That Still Paid

The appellate opinion described allegations that three identified physicians each received between $20,000 and $22,500 for canceled events over a two-year period. Each also allegedly submitted $1 to $1.7 million in Medicare Part D claims in that period. The court found those details sufficient to let this part of the alleged kickback scheme proceed.

The earlier complaint explained how a cancellation could preserve the fee:

The complaint alleged that staff received this encouragement even when invitations had not gone out, advertising had not appeared or reservations were low or nonexistent. It separately alleged that verbal reservations let Peer-to-Peer programs qualify for payment despite cancellation or attendance below the required minimum.

The event could disappear while the payment survived. The alleged bargain paid doctors for talks nobody gave, with taxpayers funding the prescriptions. Cancellation messages, reservation records and payment approvals would tell the story of the same engagement from different sides.

3. Speaking Work Tied to Prescription Volume

The appellate opinion described a Chicago physician whose nurse allegedly told a sales representative that the physician would not prescribe Gilenya without speaking engagements. The representative’s manager allegedly instructed the representative to arrange them. When that doctor’s prescriptions declined, the manager allegedly wanted him used as a speaker because his numbers were down.

Another manager allegedly selected a physician for her potential prescription volume, and the complaint said her prescribing increased after she became a speaker. It also described calls about finding more paid opportunities for a high-volume Delaware prescriber after patient programs decreased.

A prescription report can show what a sales team measured. A manager’s instruction to give a particular doctor another paid engagement can show what the team did with the measurement. The allegation was that prescription volume drove the speaking invitations.

A 2012 review from the Nordic Cochrane Centre, Corporate Crime in the Pharmaceutical Industry Is Common, Serious and Repetitive, describes an earlier version of that business practice. It reports that Warner-Lambert tracked high-volume prescribers and rewarded them with speaking, consulting or patient-recruitment work. The review places prescribing data inside the process of choosing who receives paid work, the same connection at issue in the Gilenya allegations.

The Records Behind the Speaker Fee

The useful evidence in this case connects an event, its payment and the decision to reward a particular prescriber. An employee who scheduled programs may know why a nearly empty event remained on the calendar. A payment reviewer may know why a canceled talk still produced a fee. A sales specialist may know why a doctor whose prescriptions had dropped suddenly received another invitation to speak.

There is a close parallel in the Biogen complaint. The whistleblower alleged that marketing managers decided how many consulting meetings to hold and how much to pay doctors before staff developed the topics. The same complaint alleged that Biogen trained additional speakers to blunt Gilenya’s entry into the market, despite having more trained speakers than it could use.

The connection is the order of the decisions: choose the prescriber and the payment opportunity, then supply the educational occasion. That is a recurring question in pharmaceutical fraud cases, and one that people inside sales and event operations can often explain in concrete terms.

For pharmaceutical whistleblowers, the value of that knowledge lies in connecting the company’s stated purpose with its actual decisions. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know Why the Speaker Was Chosen

If you saw speaking opportunities follow prescription targets or watched canceled programs keep paying, speak with our whistleblower experts about who got paid and why. We work with you to build your strongest pharmaceutical whistleblower case, bring in pharmaceutical kickback whistleblower lawyers who understand speaker-payment schemes, and stay beside you through the pursuit of a recovery.